{"id":11695,"date":"2025-04-14T21:46:07","date_gmt":"2025-04-14T21:46:07","guid":{"rendered":"https:\/\/latamreports.com\/br\/?p=11695"},"modified":"2025-04-14T21:46:10","modified_gmt":"2025-04-14T21:46:10","slug":"anvisa-aprova-primeira-vacina-contra-chikungunya-desenvolvida-pelo-instituto-butantan","status":"publish","type":"post","link":"https:\/\/latamreports.com\/br\/anvisa-aprova-primeira-vacina-contra-chikungunya-desenvolvida-pelo-instituto-butantan\/","title":{"rendered":"Anvisa aprova primeira vacina contra chikungunya desenvolvida pelo Instituto Butantan"},"content":{"rendered":"\n<p>A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (<a href=\"https:\/\/latamreports.com\/br\/implantes-hormonais-anvisa-estabelece-novas-regras-para-uso-e-controle\/\">Anvisa<\/a>) aprovou, nesta segunda-feira, 14, o registro definitivo da vacina contra a chikungunya desenvolvida pelo Instituto Butantan, em parceria com a farmac\u00eautica franco-austr\u00edaca Valneva. O imunizante, denominado IXCHIQ, \u00e9 o primeiro autorizado no Brasil para combater a doen\u00e7a e est\u00e1 indicado para pessoas com 18 anos ou mais. <\/p>\n\n\n\n<p>A chikungunya \u00e9 uma doen\u00e7a viral transmitida pelos mosquitos Aedes aegypti e Aedes albopictus, os mesmos vetores da dengue e do zika v\u00edrus. <\/p>\n\n\n\n<h6 class=\"wp-block-heading\">Em 2024, foram registrados aproximadamente 620 mil casos da doen\u00e7a em todo o mundo, com maior incid\u00eancia no Brasil, Paraguai, Argentina e Bol\u00edvia.\u200b<\/h6>\n\n\n\n<p>A <a href=\"https:\/\/latamreports.com\/br\/anvisa-suspende-implantes-hormonais-esteticos-conhecidos-como-chip-da-beleza\/\">vacina <\/a>IXCHIQ \u00e9 de dose \u00fanica e demonstrou alta efic\u00e1cia nos estudos cl\u00ednicos. Em ensaios realizados nos Estados Unidos com 4 mil volunt\u00e1rios de 18 a 65 anos, 98,9% dos participantes desenvolveram anticorpos neutralizantes contra o v\u00edrus, com n\u00edveis mantidos por pelo menos seis meses. Resultados semelhantes foram observados em estudos com adolescentes brasileiros, publicados na revista cient\u00edfica The Lancet Infectious Diseases em setembro de 2024.<\/p>\n\n\n\n<p>Os eventos adversos mais comuns relatados ap\u00f3s a vacina\u00e7\u00e3o foram leves ou moderados, incluindo dor de cabe\u00e7a, dor no corpo, fadiga e febre. A vacina \u00e9 contraindicada para gestantes, pessoas imunodeficientes ou imunossuprimidas.<\/p>\n\n\n\n<p>Com a aprova\u00e7\u00e3o da Anvisa, o Instituto Butantan trabalha na adapta\u00e7\u00e3o da vacina para produ\u00e7\u00e3o nacional, visando sua incorpora\u00e7\u00e3o ao Sistema \u00danico de Sa\u00fade (SUS). A inclus\u00e3o no Programa Nacional de Imuniza\u00e7\u00f5es depender\u00e1 de an\u00e1lise da Comiss\u00e3o Nacional de Incorpora\u00e7\u00e3o de Tecnologias no SUS (Conitec) e de outras autoridades de sa\u00fade. A expectativa \u00e9 que a vacina\u00e7\u00e3o seja priorizada em regi\u00f5es end\u00eamicas, onde h\u00e1 maior concentra\u00e7\u00e3o de casos da doen\u00e7a.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) aprovou, nesta segunda-feira, 14, o registro definitivo da vacina contra a chikungunya desenvolvida pelo Instituto Butantan, em parceria &#8230; <a title=\"Anvisa aprova primeira vacina contra chikungunya desenvolvida pelo Instituto Butantan\" class=\"read-more\" href=\"https:\/\/latamreports.com\/br\/anvisa-aprova-primeira-vacina-contra-chikungunya-desenvolvida-pelo-instituto-butantan\/\" aria-label=\"Read more about Anvisa aprova primeira vacina contra chikungunya desenvolvida pelo Instituto Butantan\">Read more<\/a><\/p>\n","protected":false},"author":7,"featured_media":11696,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[2,13],"tags":[31],"class_list":["post-11695","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-negocios","category-politica","tag-brasil","resize-featured-image"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Anvisa aprova primeira vacina contra chikungunya<\/title>\n<meta name=\"description\" content=\"A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) aprovou, nesta segunda-feira (14), o registro definitivo da vacina contra a chikungunya\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/latamreports.com\/br\/anvisa-aprova-primeira-vacina-contra-chikungunya-desenvolvida-pelo-instituto-butantan\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Anvisa aprova primeira vacina contra chikungunya\" \/>\n<meta property=\"og:description\" content=\"A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) aprovou, nesta segunda-feira (14), o registro definitivo da vacina contra a chikungunya\" \/>\n<meta property=\"og:url\" content=\"https:\/\/latamreports.com\/br\/anvisa-aprova-primeira-vacina-contra-chikungunya-desenvolvida-pelo-instituto-butantan\/\" \/>\n<meta property=\"og:site_name\" content=\"LatAm Reports\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/facebook.com\/latamreports\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-14T21:46:07+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-14T21:46:10+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/latamreports.com\/br\/wp-content\/uploads\/design-2025-04-14T174119.608.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"630\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"LatAm Reports Redatores da Equipe\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@latamreports\" \/>\n<meta name=\"twitter:site\" content=\"@latamreports\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"LatAm Reports Redatores da Equipe\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/anvisa-aprova-primeira-vacina-contra-chikungunya-desenvolvida-pelo-instituto-butantan\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/anvisa-aprova-primeira-vacina-contra-chikungunya-desenvolvida-pelo-instituto-butantan\\\/\"},\"author\":{\"name\":\"LatAm Reports Redatores da Equipe\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#\\\/schema\\\/person\\\/a561f2de7e5ccabfab38d239b39fdb70\"},\"headline\":\"Anvisa aprova primeira vacina contra chikungunya desenvolvida pelo Instituto Butantan\",\"datePublished\":\"2025-04-14T21:46:07+00:00\",\"dateModified\":\"2025-04-14T21:46:10+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/anvisa-aprova-primeira-vacina-contra-chikungunya-desenvolvida-pelo-instituto-butantan\\\/\"},\"wordCount\":302,\"publisher\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/anvisa-aprova-primeira-vacina-contra-chikungunya-desenvolvida-pelo-instituto-butantan\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/latamreports.com\\\/br\\\/wp-content\\\/uploads\\\/design-2025-04-14T174119.608.png\",\"keywords\":[\"Brasil\"],\"articleSection\":[\"Neg\u00f3cios\",\"Pol\u00edtica\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/anvisa-aprova-primeira-vacina-contra-chikungunya-desenvolvida-pelo-instituto-butantan\\\/\",\"url\":\"https:\\\/\\\/latamreports.com\\\/br\\\/anvisa-aprova-primeira-vacina-contra-chikungunya-desenvolvida-pelo-instituto-butantan\\\/\",\"name\":\"Anvisa aprova primeira vacina contra chikungunya\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/anvisa-aprova-primeira-vacina-contra-chikungunya-desenvolvida-pelo-instituto-butantan\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/anvisa-aprova-primeira-vacina-contra-chikungunya-desenvolvida-pelo-instituto-butantan\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/latamreports.com\\\/br\\\/wp-content\\\/uploads\\\/design-2025-04-14T174119.608.png\",\"datePublished\":\"2025-04-14T21:46:07+00:00\",\"dateModified\":\"2025-04-14T21:46:10+00:00\",\"description\":\"A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) aprovou, nesta segunda-feira (14), o registro definitivo da vacina contra a chikungunya\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/anvisa-aprova-primeira-vacina-contra-chikungunya-desenvolvida-pelo-instituto-butantan\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/latamreports.com\\\/br\\\/anvisa-aprova-primeira-vacina-contra-chikungunya-desenvolvida-pelo-instituto-butantan\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/anvisa-aprova-primeira-vacina-contra-chikungunya-desenvolvida-pelo-instituto-butantan\\\/#primaryimage\",\"url\":\"https:\\\/\\\/latamreports.com\\\/br\\\/wp-content\\\/uploads\\\/design-2025-04-14T174119.608.png\",\"contentUrl\":\"https:\\\/\\\/latamreports.com\\\/br\\\/wp-content\\\/uploads\\\/design-2025-04-14T174119.608.png\",\"width\":1200,\"height\":630,\"caption\":\"Anvisa aprova primeira vacina contra chikungunya desenvolvida pelo Instituto Butantan\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/anvisa-aprova-primeira-vacina-contra-chikungunya-desenvolvida-pelo-instituto-butantan\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/latamreports.com\\\/br\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Anvisa aprova primeira vacina contra chikungunya desenvolvida pelo Instituto Butantan\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#website\",\"url\":\"https:\\\/\\\/latamreports.com\\\/br\\\/\",\"name\":\"LatAm Reports\",\"description\":\"Not\u00edcias e opini\u00f5es de todas as Am\u00e9ricas\",\"publisher\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/latamreports.com\\\/br\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#organization\",\"name\":\"LatAm Reports\",\"url\":\"https:\\\/\\\/latamreports.com\\\/br\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/latamreports.com\\\/br\\\/wp-content\\\/uploads\\\/cropped-PNG2.png\",\"contentUrl\":\"https:\\\/\\\/latamreports.com\\\/br\\\/wp-content\\\/uploads\\\/cropped-PNG2.png\",\"width\":2522,\"height\":1014,\"caption\":\"LatAm Reports\"},\"image\":{\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/facebook.com\\\/latamreports\",\"https:\\\/\\\/x.com\\\/latamreports\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/latamreports.com\\\/br\\\/#\\\/schema\\\/person\\\/a561f2de7e5ccabfab38d239b39fdb70\",\"name\":\"LatAm Reports Redatores da Equipe\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/dcdcc93cc5edddd2f3ef77245866172c7d7241a11ad58e1959aa824f2fae81f6?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/dcdcc93cc5edddd2f3ef77245866172c7d7241a11ad58e1959aa824f2fae81f6?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/dcdcc93cc5edddd2f3ef77245866172c7d7241a11ad58e1959aa824f2fae81f6?s=96&d=mm&r=g\",\"caption\":\"LatAm Reports Redatores da Equipe\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Anvisa aprova primeira vacina contra chikungunya","description":"A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) aprovou, nesta segunda-feira (14), o registro definitivo da vacina contra a chikungunya","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/latamreports.com\/br\/anvisa-aprova-primeira-vacina-contra-chikungunya-desenvolvida-pelo-instituto-butantan\/","og_locale":"en_US","og_type":"article","og_title":"Anvisa aprova primeira vacina contra chikungunya","og_description":"A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) aprovou, nesta segunda-feira (14), o registro definitivo da vacina contra a chikungunya","og_url":"https:\/\/latamreports.com\/br\/anvisa-aprova-primeira-vacina-contra-chikungunya-desenvolvida-pelo-instituto-butantan\/","og_site_name":"LatAm Reports","article_publisher":"https:\/\/facebook.com\/latamreports","article_published_time":"2025-04-14T21:46:07+00:00","article_modified_time":"2025-04-14T21:46:10+00:00","og_image":[{"width":1200,"height":630,"url":"https:\/\/latamreports.com\/br\/wp-content\/uploads\/design-2025-04-14T174119.608.png","type":"image\/png"}],"author":"LatAm Reports Redatores da Equipe","twitter_card":"summary_large_image","twitter_creator":"@latamreports","twitter_site":"@latamreports","twitter_misc":{"Written by":"LatAm Reports Redatores da Equipe","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/latamreports.com\/br\/anvisa-aprova-primeira-vacina-contra-chikungunya-desenvolvida-pelo-instituto-butantan\/#article","isPartOf":{"@id":"https:\/\/latamreports.com\/br\/anvisa-aprova-primeira-vacina-contra-chikungunya-desenvolvida-pelo-instituto-butantan\/"},"author":{"name":"LatAm Reports Redatores da Equipe","@id":"https:\/\/latamreports.com\/br\/#\/schema\/person\/a561f2de7e5ccabfab38d239b39fdb70"},"headline":"Anvisa aprova primeira vacina contra chikungunya desenvolvida pelo Instituto Butantan","datePublished":"2025-04-14T21:46:07+00:00","dateModified":"2025-04-14T21:46:10+00:00","mainEntityOfPage":{"@id":"https:\/\/latamreports.com\/br\/anvisa-aprova-primeira-vacina-contra-chikungunya-desenvolvida-pelo-instituto-butantan\/"},"wordCount":302,"publisher":{"@id":"https:\/\/latamreports.com\/br\/#organization"},"image":{"@id":"https:\/\/latamreports.com\/br\/anvisa-aprova-primeira-vacina-contra-chikungunya-desenvolvida-pelo-instituto-butantan\/#primaryimage"},"thumbnailUrl":"https:\/\/latamreports.com\/br\/wp-content\/uploads\/design-2025-04-14T174119.608.png","keywords":["Brasil"],"articleSection":["Neg\u00f3cios","Pol\u00edtica"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/latamreports.com\/br\/anvisa-aprova-primeira-vacina-contra-chikungunya-desenvolvida-pelo-instituto-butantan\/","url":"https:\/\/latamreports.com\/br\/anvisa-aprova-primeira-vacina-contra-chikungunya-desenvolvida-pelo-instituto-butantan\/","name":"Anvisa aprova primeira vacina contra chikungunya","isPartOf":{"@id":"https:\/\/latamreports.com\/br\/#website"},"primaryImageOfPage":{"@id":"https:\/\/latamreports.com\/br\/anvisa-aprova-primeira-vacina-contra-chikungunya-desenvolvida-pelo-instituto-butantan\/#primaryimage"},"image":{"@id":"https:\/\/latamreports.com\/br\/anvisa-aprova-primeira-vacina-contra-chikungunya-desenvolvida-pelo-instituto-butantan\/#primaryimage"},"thumbnailUrl":"https:\/\/latamreports.com\/br\/wp-content\/uploads\/design-2025-04-14T174119.608.png","datePublished":"2025-04-14T21:46:07+00:00","dateModified":"2025-04-14T21:46:10+00:00","description":"A Ag\u00eancia Nacional de Vigil\u00e2ncia Sanit\u00e1ria (Anvisa) aprovou, nesta segunda-feira (14), o registro definitivo da vacina contra a chikungunya","breadcrumb":{"@id":"https:\/\/latamreports.com\/br\/anvisa-aprova-primeira-vacina-contra-chikungunya-desenvolvida-pelo-instituto-butantan\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/latamreports.com\/br\/anvisa-aprova-primeira-vacina-contra-chikungunya-desenvolvida-pelo-instituto-butantan\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/latamreports.com\/br\/anvisa-aprova-primeira-vacina-contra-chikungunya-desenvolvida-pelo-instituto-butantan\/#primaryimage","url":"https:\/\/latamreports.com\/br\/wp-content\/uploads\/design-2025-04-14T174119.608.png","contentUrl":"https:\/\/latamreports.com\/br\/wp-content\/uploads\/design-2025-04-14T174119.608.png","width":1200,"height":630,"caption":"Anvisa aprova primeira vacina contra chikungunya desenvolvida pelo Instituto Butantan"},{"@type":"BreadcrumbList","@id":"https:\/\/latamreports.com\/br\/anvisa-aprova-primeira-vacina-contra-chikungunya-desenvolvida-pelo-instituto-butantan\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/latamreports.com\/br\/"},{"@type":"ListItem","position":2,"name":"Anvisa aprova primeira vacina contra chikungunya desenvolvida pelo Instituto Butantan"}]},{"@type":"WebSite","@id":"https:\/\/latamreports.com\/br\/#website","url":"https:\/\/latamreports.com\/br\/","name":"LatAm Reports","description":"Not\u00edcias e opini\u00f5es de todas as Am\u00e9ricas","publisher":{"@id":"https:\/\/latamreports.com\/br\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/latamreports.com\/br\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/latamreports.com\/br\/#organization","name":"LatAm Reports","url":"https:\/\/latamreports.com\/br\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/latamreports.com\/br\/#\/schema\/logo\/image\/","url":"https:\/\/latamreports.com\/br\/wp-content\/uploads\/cropped-PNG2.png","contentUrl":"https:\/\/latamreports.com\/br\/wp-content\/uploads\/cropped-PNG2.png","width":2522,"height":1014,"caption":"LatAm Reports"},"image":{"@id":"https:\/\/latamreports.com\/br\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/facebook.com\/latamreports","https:\/\/x.com\/latamreports"]},{"@type":"Person","@id":"https:\/\/latamreports.com\/br\/#\/schema\/person\/a561f2de7e5ccabfab38d239b39fdb70","name":"LatAm Reports Redatores da Equipe","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/dcdcc93cc5edddd2f3ef77245866172c7d7241a11ad58e1959aa824f2fae81f6?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/dcdcc93cc5edddd2f3ef77245866172c7d7241a11ad58e1959aa824f2fae81f6?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/dcdcc93cc5edddd2f3ef77245866172c7d7241a11ad58e1959aa824f2fae81f6?s=96&d=mm&r=g","caption":"LatAm Reports Redatores da Equipe"}}]}},"jetpack_publicize_connections":[],"_links":{"self":[{"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/posts\/11695","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/comments?post=11695"}],"version-history":[{"count":1,"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/posts\/11695\/revisions"}],"predecessor-version":[{"id":11697,"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/posts\/11695\/revisions\/11697"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/media\/11696"}],"wp:attachment":[{"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/media?parent=11695"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/categories?post=11695"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/latamreports.com\/br\/wp-json\/wp\/v2\/tags?post=11695"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}